# Selecta Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/selecta-biosciences

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.selectabio.com
- Total disclosed funding: $123M
- Latest round: Series E (Sep 8, 2015)
- Investors on record: 10

## About

Selecta Biosciences, Inc. focuses on innovative therapies utilizing a proprietary mRNA platform to enhance immune responses, primarily targeting autoimmune diseases through advanced cell therapies.Selecta Biosciences, Inc. is a biotechnology firm founded in 2008 and based in Watertown, US. The company specializes in developing mRNA-based therapies for autoimmune conditions. Its founder, Omid Farokhzad, previously established other ventures. In June 2016, Selecta raised USD 70 mn through a VENTURE DEBT round, with notable investors including Oxford Finance and Silicon Valley Bank.Selecta Biosciences specializes in mRNA therapies designed to treat autoimmune diseases, leveraging a proprietary platform for direct delivery of therapeutic proteins to patient cells. Their products are aimed at healthcare providers addressing unmet medical needs, particularly in North America and Europe.For the year 2024, Selecta Biosciences reported a revenue of USD 38.91 mn and an EBITDA of USD -42.75 mn, generated through collaborations with healthcare institutions focused on mRNA therapy development.Selecta Biosciences aims to launch new mRNA-based products targeting autoimmune diseases and is actively pursuing expansion into additional markets within North America and Europe by the end of 2025. The funds raised in June 2016 are intended to support these initiatives and enhance their R&D capabilities.

## Funding rounds

- Series E, Sep 8, 2015, $38M — Flagship Pioneering, OrbiMed Advisors, Polaris Partners, OUP (Osage University Partners), AJU IB Investment, +ND Capital, Sanofi Ventures, Sphera Fund Management, RUSNANO Management Company, Ridgeback Capital Management
- Series D, Apr 7, 2014, $5.3M — Flagship Pioneering, OrbiMed Advisors, +ND Capital
- Series D, Nov 17, 2011, $47M — Flagship Pioneering, OrbiMed Advisors, Polaris Partners, +ND Capital, RUSNANO Management Company
- Series C, Mar 22, 2010, $15M — Flagship Pioneering, OrbiMed Advisors, Polaris Partners, +ND Capital
- Series B, Feb 25, 2009, $15M — Flagship Pioneering, Polaris Partners, +ND Capital
- Series A, May 2, 2008, $2.3M — Flagship Pioneering, Polaris Partners

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B, Series C, Series D, Series E
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C, Series D, Series E
- +ND Capital (https://capitalatlas.ai/funds/nd-capital) — Series B, Series C, Series D, Series E
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C, Series D, Series E
- RUSNANO Management Company — Series D, Series E
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series E
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series E
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series E
- Sphera Fund Management — Series E
- Ridgeback Capital Management — Series E